- Plasma glycosaminoglycans and cell-free DNA to discriminate benign
- 2 and malignant lung diseases
- 3 Running title: Glycosaminoglycans & cfDNA in Lung Cancer
- 4 Family name followed by given name: Qvick Alvida<sup>1</sup>, Bratulic Sinisa<sup>2</sup>, Carlsson Jessica<sup>3</sup>,
- 5 Stenmark Bianca<sup>1</sup>, Karlsson Christina<sup>4</sup>, Nielsen Jens<sup>2,5</sup>, Gatto Francesco<sup>2,6</sup>, Helenius Gisela<sup>1</sup>
- 6 Affiliations

10

14

15 16

- 7 1) Dept. of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, 701 82 Örebro, Sweden
  - 2) Department of Life Sciences, Chalmers University of Technology, 412 96 Gothenburg, Sweden
- 11 3) Dept. of Urology, Faculty of Medicine and Health, Örebro University,701 82 Örebro, Sweden
- 4) School of Health Sciences, Örebro University, 701 82 Örebro, Sweden
  - 5) BioInnovation Institute, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark
    - 6) Department of Oncology-Pathology, Karolinska Institute, 171 77 Stockholm, Sweden
- 18 Correspondence to: Alvida Qvick
- 19 Email: alvida.qvick@regionorebrolan.se
- 20 Adress: Dep. of Laboratory Medicine, Örebro University Hospital,
- Södra Grev. Roseng., 701 85 Örebro, Sweden
- 22 Bianca Stenmark: bianca.stenmark@regionorebrolan.se
- 23 Jessica Carlsson: jessica.carlsson@regionorebrolan.se
- 24 Sinisa Bratulic: bratulic@chalmers.se, sinisa.bratulic@elypta.com
- 25 Christina Karlsson: Christina.Karlsson@oru.se
- Francesco Gatto: francesco.gatto@ki.se
- 27 Jens Nielsen: nielsenj@chalmers.se
- 28 Gisela Helenius: gisela.helenius@regionorebrolan.se
- 29 All authors have read and approved the final version of this manuscript.
- 30 COTFITION of print constrained research that has not been certified by peer review and should not be used to guide clinical practice.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

F. Gatto and J. Nielsen are shareholders in Elypta AB. F. Gatto and S. Bratulic are employed at Elypta AB. J. Nielsen is a board member at Elypta AB. Elypta AB has a commercial interest in part of the technology described in this study. Remaining authors have no conflicts to declare. 1. Abstract We aimed to investigate the use of free glycosaminoglycan profiles (GAGomes) and cfDNA in plasma to differentiate between lung cancer and benign lung disease. GAGs were analyzed using the MIRAM® Free Glycosaminoglycan Kit with ultra-high-performance liquid chromatography and electrospray ionization triple-quadrupole mass spectrometry. We detected two GAGome features, 0S chondroitin sulfate (CS) and 4S CS, with cancer-specific changes. Based on the observed GAGome changes, we devised a model to predict lung cancer. The model, named the GAGome score, could detect lung cancer with 41.2% sensitivity (95% CI: 9.2-54.2%) at 96.4% specificity (CI: 95.2-100.0%, n=113). Furthermore, we found that the GAGome score, when combined with a cfDNA test, could increase the sensitivity for lung cancer from 42.6% (95% CI: 31.7-60.6%, cfDNA alone) to 70.5% (CI: 57.4 - 81.5%) at 95% specificity (CI: 75.1-100%, n=74). Notably, the combined GAGome and cfDNA testing improved the sensitivity, especially in early stages, relative to the cfDNA alone. Our findings show that plasma GAGome profiles can enhance cfDNA testing performance, highlighting the applicability of a multiomics approach in lung cancer diagnostics.

Keywords: cfDNA/GAGome/glycosaminoglycans/lung cancer/multiomics

## 2. Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

The use of high-throughput sequencing to analyze the genome and its aberrations has advanced diagnostics, predictive testing, and monitoring for many types of cancer. To avoid the challenges of obtaining tissue biopsies for cancers like lung cancer (LC), a liquid biopsy has emerged as a promising alternative. Numerous articles have been published on sequencing of circulating cell-free DNA (cfDNA) for such cancers<sup>1</sup>. Despite technical advances, which improved the sensitivity of genomics-only liquid biopsy assays, many cancers remain undetected. This can be due to technical as well as biological reasons since the released amount of circulating tumor DNA is very heterogeneous between different tumors<sup>2</sup>. To overcome this limitation, the field has turned beyond genomics to a combination of different omics techniques, referred to as multiomics, including combined information from genomics, transcriptomics, proteomics, methylomics, metabolomics, extracellular vesicles, and circulating tumor cells among others<sup>3–8</sup>. Glycosaminoglycans (GAGs) are unbranched linear polysaccharides that can be divided into four main classes: chondroitin sulfate, heparin sulfate, keratan sulfate, and hyaluronic acid<sup>9</sup>. The sulfation and glycosylation patterns in GAG chains can vary widely, leading to a very high structural and functional diversity of resulting GAG molecules 10. GAGs play crucial roles in cellular functions, including maintaining the extracellular matrix structure and providing hydration to cells. They are also integral to the immune response<sup>11,12</sup>, tissue homeostasis, as well as cell growth, proliferation, differentiation, and adhesion<sup>13</sup>. Notably, GAGs have been implicated in different aspects of cancer development and progression due to their involvement in the tumor microenvironment, through their interaction with growth factors, growth factor receptors, and cytokines 14. The disaccharide composition of GAGs in tumor tissue, plasma, and urine has been shown to be altered in several cancer types such as breast, prostate, gastric, and renal cell carcinoma<sup>15–19</sup>. Conversely, only a few studies

78 measured the structural profile of GAG disaccharides (or GAGome) in tissue or liquid 79 biopsies in  $LC^{20,21}$ , indicating the need for further research. 80 This study aimed to explore the plasma GAGome's potential for differentiating LC from non-81 malignant lung diseases via liquid biopsy. Additionally, we investigated if combining 82 GAGome and cfDNA data could increase the sensitivity and specificity to detect LC. 3. Materials and Methods 83 3.1 Study design and cohort characteristics 84 This study was reported in compliance with the Standards for Reporting of Diagnostic 85 Accuracy (STARD) guidelines<sup>22</sup> (Table S1). Study participants were enrolled into the study 86 87 during routine clinical investigation, at the lung clinic at Örebro University Hospital, between 88 February 2016 and February 2019. Patients investigated for the suspicion of LC were 89 included in the study and formed a consecutive series. To ensure the most accurate diagnosis, 90 all LC cases were histologically confirmed on tumor tissue. Patients diagnosed with cancer of 91 other origin than lung, sample not collected prior to treatment start, or with inadequate tumor 92 material for diagnosis, were excluded from the study. Participants gave written informed consent before inclusion and the study was approved by the regional ethics committee board 93 94 in Uppsala (Approval 2015-400, 2021-01478). 95 Tumors were staged and histologically classified according to the guidelines of the 96 International Association for the Study of Lung Cancer (IASLC) and the World Health Organization nomenclature, respectively<sup>23,24</sup>. Patients with benign lung diseases mainly 97 consisted of different pulmonary obstructive diseases, inflammatory conditions in the lung, 98 99 fibrosis in the lung or benign lung nodules.

### 3.2 Plasma collection and isolation

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

Blood was collected in Cell-Free RNA<sup>TM</sup> BCT tubes (Streck, Omaha, NE) and plasma was retrieved by a two-step centrifugation; 2000×g for 10 min followed by 16 000×g for 10 min. Plasma was stored at -80° C until preparation for analysis. Samples were thawed on ice and an aliquot of each sample was taken for further analyses. 3.3 GAGome measurements Plasma GAGome measurements were performed retrospectively in a single blinded Good Laboratory Practice (GLP)-compliant central laboratory using MIRAM® Free Glycosaminoglycan Kit (Elypta AB, Sweden), which is a standardized kit for GAG extraction, detection, and quantification by ultra-high-performance liquid chromatography (UHPLC) coupled with electrospray ionization triple-quadrupole mass spectrometry system (ESI-MS/MS, Acquity I-class Plus Xevo TQ-S micro, Waters® Corporation, MA). A single UHPLC column equipped with a pre-column guard (Waters® ACOUITY UPLC BEH C18 VanGuard Pre-column) was sufficient to analyze all samples in this study with no quality deterioration observed over time. The analytical performance characteristics of the kit have been previously described<sup>25</sup>. In short, the kit is based on a method by Volpi et al. (2014)<sup>26</sup>. The assay consists of the enzymatic depolymerization of GAGs from the sample into disaccharides by *Chondroitinase* ABC and Heparinase I-II-III. The method omits proteolytic digestion, thereby limiting the derived depolymerized GAGs to the protein-free fraction – or free GAGs. Following depolymerization, disaccharides are labeled using 2-aminoacridone and injected into an UHPLC-MS/MS for separation and detection. The peaks of the 17 disaccharides are acquired at using multiple reaction monitoring analysis implemented in the mass spectrometry software (Waters® TargetLynx). The chromatographic conditions and MS configuration were set in accordance with the kit instruction for use.

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Each sample was measured in singleton. The so-measured GAGome consisted of the absolute concentrations of 17 GAG disaccharides, corresponding to eight different sulfation patterns of chondroitin sulfate (CS) and heparan sulfate (HS), and one hyaluronic acid (HA) disaccharide. Specifically, we quantified eight CS disaccharides (0S CS, 2S CS, 6S CS, 4S CS, 2S6S CS, 2S4S CS, 4S6S CS, and TriS CS) and eight HS disaccharides (0S HS, 2S HS, 6S HS, NS HS, NS6S HS, NS2S HS, 2S6S HS, and TriS HS). We expanded the GAGome to include an additional 22 calculated features informative of GAG biology: a) the total CS and total HS concentration as the sum of the corresponding disaccharide concentrations, b) the CS charge [-] and HS charge [-] as the weighted sum of sulfated disaccharides, where the weight is the count of sulfo- groups in each disaccharide, c) two ratios (4S CS/0S CS and 6S CS/0S CS), and d) the relative concentration (or mass fraction, in µg/µg %) of each of the 16 CS and HS disaccharides by normalizing each absolute concentration by the total CS and HS concentration, respectively. For each sample, the GAGome consisted of maximally 39 features. We considered a GAGome feature detectable in plasma if the median concentration across all samples was above 0.1 µg/mL<sup>25</sup>. GAGome features that did not fulfill this criterion were excluded from downstream analyses. 3.4 cfDNA data For 81 of the 113 samples, cfDNA concentration measurement was available. The cfDNA was extracted from 4 mL plasma using the QIAsymphony DSP Circulating DNA kit on the QIAsymphony SP system (Qiagen, Germany) according to the manufacturer's instructions. The concentration was measured using dsDNA HS assay kit (Thermo Fisher) on Oubit 2.0 Fluorometer (Thermo Fisher). Out of the samples with available cfDNA concentration measurements, 74 samples also had NGS data available, which have been published

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

previously<sup>27</sup>. The NGS panel used was AVENIO ctDNA Surveillance kit (Roche Diagnostics, Rotkreuz, Switzerland), which includes 197 cancer relevant genes. 3.5 Statistical analysis Continuous data were presented using mean and median values while categorical data were presented using absolute and relative frequencies. Differences between LC patients and controls regarding general clinical characteristics were investigated using  $\chi^2$ -tests for categorical variables and Student's t-tests for continuous data. 3.5.1 GAGome analysis We compared levels of each detectable GAGome feature in cancer versus control participants using Bayesian estimation with practical equivalence testing<sup>28</sup>. First, we fitted a Bayesian linear regression where each individual GAGome feature was standardized and modelled as a normally distributed response variable and the disease state (case vs control) was the only binary predictor. Second, we controlled the correlation between GAGome measurements in cancer vs controls for technical variation by fitting Bayesian linear models as above but including experimental batch (binary) and sample age (continuous, in months) as predictors. We used a t-distribution centered on 0 with 7 degrees of freedom, and scale = 2 for all the priors in all the Bayesian models. We fit the models using rstanarm package (ver 2.21.3) in R (ver. 4.2.1). The convergence and stability of the Bayesian sampling was assessed using R-hat, which should be below 1.01 <sup>29</sup> and Effective Sample Size (ESS), which should be greater than 1000<sup>30</sup>. The same convergence criteria were used for all Bayesian models. A GAGome feature was considered credibly associated to case-control status if the 95% confidence interval (CI) of the difference in means did not include zero, and no more than 10% of the CI passed into the Region of Practical Equivalence (ROPE)<sup>28</sup>. The ROPE-interval was defined as [-0.1, 0.1] of the standardized mean, corresponding to a negligible effect size<sup>31</sup>. GAGome features that were credibly associated with case-control status after adjusting the

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

linear regression model for experimental batch and sample age were further analyzed as predictors of cancer in the GAGome score development. 3.5.2 GAGome score development A Bayesian logistic model was fitted to predict case vs control using the absolute concentration of OS CS (in µg/mL) and the fraction of 4S CS (in µg/µg %) as predictors. The predictors were batch-normalized before fitting the model. The Markov chain Monte Carlo (MCMC) sampling was performed with four chains of 10 000 iterations and a warmup of 5000. The output of the model is referred to as *plasma GAGome LC score*, or simply *GAGome score*. Model metrics were investigated using a bootstrap analysis with 5000 bootstraps, under a constraint of minimum 95% specificity, which was deemed potentially clinically useful. The final model performance for detecting case vs control was evaluated by calculating sensitivity at 95% specificity, and an area under the curve (AUC) for the model. 3.5.3 cfDNA score development Bayesian logistic models (estimated using MCMC sampling) were fitted to predict case-control status using cfDNA concentration (logarithmic) in combination with the number of cfDNA variants. The output of the model is referred to as *cfDNA score*. 3.5.4 Combined GAGome and cfDNA test pathway A combined test was envisioned as a diagnostic pathway that sequentially uses the cfDNA score and the GAGome score to render a diagnostic decision, i.e. "combined test positive" vs "combined test negative". To cumulatively retain the 95% specificity for the combined test, as was rationalized for the GAGome score, the GAGome specificity was kept at 95% while the specificity for the cfDNA score was set to 100%. Specifically, the GAGome score, when positive, could be used to reclassify cfDNA score false negative samples as "combined test positive". The testing procedure was as following: 1) calculate the cfDNA score cut-off at which a minimum of 100% specificity was achieved, 2) calculate the GAGome score cut-off at which a minimum of 95% specificity was achieved, 3) for each sample, consider it positive for the cfDNA score, if the sample score was above the cut-off; analogously for the GAGome score, 4) for each sample, consider it positive for the combined test if at least one between the cfDNA and GAGome score were positive, 5) mark samples which were cfDNA score-negative but GAGome score-positive as "reclassified positive".

## 4. Results

### 4.1 Cohort characteristics

The cohort comprised patients referred to the clinic under suspicion of LC (n=113). Of these, 85 cases were subsequently diagnosed with LC, which were further stratified into non-small cell LC (NSCLC, n=77) and small cell LC (SCLC, n=8). Patients diagnosed with a benign lung disease (n=28) served as controls (Table 1). Cases were slightly older than controls (mean 70.4 vs 67.0 years) and more evenly distributed among the sexes (52.9% females vs 60.7% females), neither characteristic showed a significant difference. A history of smoking was more prevalent among cases compared to controls (85.9% vs 60.8%, p=0.047). The predominant tumor stage was stage IV (61.2%), with a mean tumor size of 4.48 cm.

**Table 1.** Clinical characteristics of the cohort. Cases include patients diagnosed with lung cancer, irrespective of histology, and controls include patients diagnosed with different benign diseases of the lung.

	Case (n=85)	Control (n=28)	Lung cancer vs Controls, p-value	Overall (N=113)
Age				
Mean (SD)	70.4 (8.5)	67.0 (14.4)	0.246	69.6 (10.3)
Gender				
Female	45 (52.9%)	17 (60.7%)	0.473	63 (55.3%)
Male	40 (47.1%)	11 (39.3%)		51 (44.7%)
Smoking				
Smoker	30 (35.3%)	5 (17.9%)	0.047	35 (31.0%)
Ex-Smoker	43 (50.6%)	12 (42.9%)		55 (48.7%)
Never-Smoker	12 (14.1%)	9 (32.1%)		21 (18.6%)
Missing	0 (0%)	2 (7.1%)		2 (1.8%)


	_	_		
	Case (n=85)	Control (n=28)	Lung cancer vs Controls, p-value	Overall (N=113)
Tumor size (cm)	· · · · · · · · · · · · · · · · · · ·	_ <del>.</del>		
Mean (SD)	4.5 (2.4)	NA (NA)		4.5 (2.4)
Median [Min, Max]	4.0 [0.9, 12.5]	NA [NA, NA]		4.0 [0.9, 12.5]
Missing	4 (4.7%)	28 (100%)		32 (28.3%)
IASLC stage				
I	9 (10.6%)	0 (0%)		9 (8.0%)
II	6 (7.1%)	0 (0%)		6 (5.3%)
III	18 (21.2%)	0 (0%)		18 (15.9%)
IV	52 (61.2%)	0 (0%)		52 (46.0%)

SD = Standard deviation, NA = Not Applicable and IASLC = International association for the study of lung cancer.

## 4.2 Correlation between plasma GAGomes and lung cancer diagnosis

The plasma GAGome, which comprised the structural characterization of 17 different GAG disaccharides, of all samples (n=113) was analyzed successfully. 4S CS and 0S CS were the only GAG disaccharides with a median detected concentration above 0.1 µg/mL. Therefore, we focused the subsequent analysis on these two independently measured features and the corresponding four derived features (Materials and methods, table S2, figure 1).

Compared to controls, cases with cancer had a nominally higher median concentration of 0S CS, and a lower concentration of 4S CS (figure 1, table S2). Concomitantly, we found that the composition of CS in cases with cancer shifted towards a lower 4S CS fraction and higher 0S CS fraction (figure 1).




**Figure 1.** Plasma GAGome profiles. Concentrations (left) and fractions (right) of plasma GAGs in cases (n=85) and controls (n=28). CS: chondroitin sulfate.

Using Bayesian linear regression and equivalence testing, we determined that two plasma GAGome features were credibly associated with LC after adjustment for batch effects and sample age (figure S1). Specifically, an increase in the plasma concentration of 0S CS and a reduction in the fraction of 4S CS were credibly correlated with LC after adjustment for confounders.

#### 4.3 GAGome and cfDNA score

We next sought to develop a *plasma GAGome LC score* (or simply, GAGome score) for discriminating LC cases and controls. We fitted a Bayesian logistic model to predict cancer (figure S2, supplementary text), where the model's output, referred to as the GAGome score, corresponded to the log-odds ratio of having LC.

The GAGome score had a 41.2% sensitivity (95% CI: 9.2-54.2%) to detect LC at a 96.4% specificity (95% CI: 95.2-100%) with an AUC of 0.67 (95% CI: 0.56-0.77, figure 2, table S3).




**Figure 2.** Performance of the GAGome score to discriminate cases and controls in A) the whole cohort and B) by IASLC stage. Controls are shown in blue ( $N_{Control} = 28$ ) and cases in orange ( $N_{Case} = 85$ ;  $N_{StageII} = 9$ ,  $N_{StageII/III} = 24$ ,  $N_{StageIV} = 58$ ). IASLC: International Association for the Study of Lung Cancer.

Next, cfDNA data was analyzed. Neither cfDNA concentration nor number of cfDNA variants were correlated to the GAGome features included in the GAGome score (0S CS concentration and 4S CS fraction, figure S3). A *cfDNA score* was generated in the subset samples for which both cfDNA concentration and number of variants were available (n=74, figure 3A). Specifically, we fitted a Bayesian logistic model to predict case vs control using cfDNA concentration and the number of cfDNA variants as predictors. The model's output, referred to as the cfDNA score, corresponded to the log-odds ratio of having LC. We treated samples where cfDNA concentration was available but insufficient for cfDNA variant

analysis (n=7) as cfDNA score negative for evaluating the cfDNA score performance. The cfDNA score had an AUC of 0.80 (95% CI: 0.685-0.903) and a 42.6% sensitivity (95% CI: 31.7-60.6%) at 100% specificity (figure 3B).

We envisioned a diagnostic pathway that relies on sequential cfDNA and GAGome measurements in plasma, specifically to use the GAGome score for potentially cfDNA scorefalse negatives. This combined test would be positive if either the cfDNA or GAGome scores were positive. We allowed for one false positive and set the threshold for cfDNA positivity at 100% specificity and GAGome score positivity at 95% specificity (figure 3). The sensitivity for the combined test increased to 70.5% (95% CI: 57.4 - 81.5%) at a specificity of 95% (95% CI: 75.1-100%, figure 3C). Notably, in this diagnostic pathway with overall 95% specificity (one false positive), the GAGome score contributed to a higher sensitivity for stage I (55.6% vs 11.1% for cfDNA alone, table S4) and stage II-III (40% vs 20% for cfDNA alone, table S4), and could correctly reclassify 17 out of 19 cases that were false negative when using the cfDNA score alone (table S5).



**Figure 3.** Performance of the combined test. A) Subject flow and inclusion for the cfDNA data. B) Performance and cutoffs for the cfDNA and GAGome score separately and C) sensitivity when combined (by IASCL stage). IASCL: International Association for the Study of Lung Cancer.

### 5. Discussion

In this study, we aimed to use GAGomes to discriminate between LC and benign lung diseases and to explore if the addition of cfDNA data could further increase the sensitivity of the developed score. We used the detected features, 0S CS and 4S CS, to build a GAGome score that reached a 41.2% sensitivity at 96.4% specificity. We next envisioned a test that combines the GAGome-score with cfDNA data to increase the diagnostic potential for LC. In the subset of patients with cfDNA data available the combined test could diagnose LC with 70.5% sensitivity at 95% sensitivity. To the best of our knowledge, this is the first study to develop a multiomics test combining GAGs and cfDNA for cancer.

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

Research on GAGs in LC has been limited, with most studies focusing on tissue-based analysis. An increase in total CS has been observed in tumor tissue compared to normal lung tissue<sup>20,21,32</sup>. However, the results regarding CS sulfation patterns have been inconsistent. Pál et al. and Balbisi et al. reported lower OS CS and higher 4S CS in tumors, while Li et al. found the opposite for 4S CS. Discrepancies between tissue and plasma can be explained by the cell origin of the molecules analyzed. Mattox et al. investigated the contribution of different cells to cfDNA in plasma and found that, even in cancer patients, over 70% of cfDNA originated from leukocytes, and only 2.2% of the fragments in LC patients originated from the lung<sup>33</sup>. They concluded that these results reflect the systemic effect of the tumor on the body, suggesting that what is detected is not primarily the tumor itself, but the effect it causes. This concept can be applied to other circulating biomarkers, such as GAGs, indicating that plasma tests should be interpreted separately from tissue tests. Circulating GAGs in plasma has only been reported once previously<sup>34</sup>, where elevated 0S CS concentration and a lower 4S CS fraction was detected in LC cases relative to controls. We found that the GAGome alone had a sensitivity of 40% for detecting LC which was comparable to 42.6% sensitivity of cfDNA. Given that GAGomes were uncorrelated with cfDNA measurements and that the GAGome score had similar sensitivity across all IASLC stages, we speculated that the two scores could be used in a combined multiomics test for LC. By combining scores derived from cfDNA and GAGs into a multiomic test we could show an increase in sensitivity to 70.5% for differentiating between LC and non-malignant lung diseases, highlighting the potential of a multiomics approach. The effectiveness of using multiomics for cancer detection was notably proposed by Cohen et al. with CancerSEEK, which analyzed mutations in cfDNA and protein levels<sup>3</sup>. They reported an overall sensitivity of 70% across all tumor types and about 59% for LC specifically. Since then, several other studies have explored the potential of multiomics as a diagnostic tool.

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

For instance, Wang et al.4 tested a combination of cfDNA variants, proteins and fragmentomics on a cohort of colorectal, esophageal, gastric, liver, lung, and ovarian cancers <sup>35</sup>. At 98% specificity, cfDNA variants alone showed a sensitivity of 46%. This increased to 60% with the addition of proteins, and further to 66% with fragmentomics. However, for LC alone, the sensitivity of the combined model only reached 38.5%. Chen et al. combined a mutational score, methylation, and serum CEA levels for distinguishing between LC and benign lung nodules, achieving a 76.9% sensitivity at a modest specificity of 58.3%. At the 95% specificity level used in our study, their sensitivity dropped to around 30% 6. D'Ambrosi et al. reported a promising 68% sensitivity at 95% specificity for diagnosing LC using platelet-derived circRNA and mRNA<sup>36</sup>. Notably, their control group primarily consisted of asymptomatic individuals, similar to Wang et al. and CancerSEEK. Our study differed in design by using patients referred to the clinic with lung-related symptoms qualifying for LC evaluation, rather than selecting a specific control group. This enhances the clinical relevance of our findings, as it better reflects real-world diagnostic challenges. Although our control cohort was more suitable compared to several other multiomics studies, it is important to note that most of these studies had a skew towards lower stages of LC, which may have negatively impacted their reported sensitivity. The only detectable plasma GAGome features in this cohort were 0S CS and 4S CS. This is consistent with previous findings using this kit, both in healthy individuals and cancer<sup>34,37</sup>. Other studies have detected additional GAGs, such as HA in plasma<sup>38</sup>. However, the methods used in those studies included proteolytic digestion, while the method used here is degradation-free, detecting only GAGs that circulate freely in the analyzed liquid. Saito et al. tested the affinity of plasmatic proteins to different GAGs and could show that approximately 7.5% of the proteins are bound to HS and dermatan sulfate, while only 0.25% are bound to CS<sup>39</sup>. This suggests that CS has a higher probability of circulating freely in plasma, supporting our findings.

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

A limitation of our study includes the relatively small sample size and lack of external cohorts for validation. A methodological limitation is that blood was collected in tubes optimized for stabilization of cells and extracellular RNA, and not immediately processed, as the stabilization reagents are effective for several days. However, GAGs are primarily degraded by highly substrate-specific enzymes in the lysosome<sup>40</sup>. Since the tubes' main function is to stabilize cells, lysosomal activity in the plasma fraction of the sample is unlikely. While an unspecific degradation in plasma cannot be ruled out, the cancer-specific alterations to GAGomes were robust to adjustment for sample age. In conclusion, we have shown that free CS can be detected in the plasma of LC patients. From this, we developed highly specific and sensitive multiomics score by combining this data with cfDNA data from NGS analysis, effectively differentiating between LC and benign lung diseases. We envision this score as a natural companion diagnostic to radiography as a broad NGS is highly relevant for LC due to the increasing number of targeted therapies available for this indication. Adding a GAGome analysis would be comparatively inexpensive, easily performed on a small aliquot of the same blood sample used for NGS analysis and could specifically increase sensitivity for detecting lower stages of cancer without affecting the false positive rate. **Funding** This work was funded by Nyckelfonden-Örebro University Hospital Research Foundation, Lions fund for cancer research Uppsala-Örebro and Uppsala-Örebro Regional research council. Data availability Data is available from the authors upon reasonable request.

# 6. References

- 1. Chen, Z. et al. Circulating cell-free DNA as a diagnostic and prognostic biomarker for
- non-small-cell lung cancer: a systematic review and meta-analysis. *Biomarkers in*
- 365 *Medicine* **14**, 587–597 (2020).
- 366 2. Bettegowda, C. et al. Detection of Circulating Tumor DNA in Early- and Late-Stage
- Human Malignancies. *Science Translational Medicine* **6**, 224ra24-224ra24 (2014).
- 368 3. Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-
- analyte blood test. *Science* **359**, 926–930 (2018).
- 4. Wang, P. et al. Simultaneous analysis of mutations and methylations in circulating cell-
- 371 free DNA for hepatocellular carcinoma detection. Science Translational Medicine 14,
- and eabp8704 (2022).
- 5. Visal, T. H., Hollander, P. den, Cristofanilli, M. & Mani, S. A. Circulating tumour cells in
- 374 the -omics era: how far are we from achieving the 'singularity'? *British Journal of Cancer*
- **127**, 173 (2022).
- 376 6. Chen, K. et al. Non-invasive lung cancer diagnosis and prognosis based on multi-analyte
- 377 liquid biopsy. *Molecular Cancer* **20**, 23 (2021).
- 7. Tomeva, E., Switzeny, O. J., Heitzinger, C., Hippe, B. & Haslberger, A. G.
- Comprehensive Approach to Distinguish Patients with Solid Tumors from Healthy
- Controls by Combining Androgen Receptor Mutation p.H875Y with Cell-Free DNA
- Methylation and Circulating miRNAs. *Cancers (Basel)* **14**, 462 (2022).
- 8. Lin, A. A., Nimgaonkar, V., Issadore, D. & Carpenter, E. L. Extracellular Vesicle–Based
- Multianalyte Liquid Biopsy as a Diagnostic for Cancer. Annu. Rev. Biomed. Data Sci. 5,
- 384 269–292 (2022).
- 9. Li, L., Ly, M. & Linhardt, R. J. Proteoglycan sequence. *Mol. BioSyst.* **8**, 1613–1625
- 386 (2012).

- 387 10. Bülow, H. E. & Hobert, O. The Molecular Diversity of Glycosaminoglycans Shapes
- Animal Development. Annual Review of Cell and Developmental Biology 22, 375–407
- 389 (2006).
- 390 11. Gray, A. L., Pun, N., Ridley, A. J. L. & Dyer, D. P. Role of extracellular matrix
- proteoglycans in immune cell recruitment. *International Journal of Experimental*
- 392 *Pathology* **103**, 34–43 (2022).
- 393 12. du Souich, P., García, A. G., Vergés, J. & Montell, E. Immunomodulatory and anti-
- inflammatory effects of chondroitin sulphate. *J Cell Mol Med* **13**, 1451–1463 (2009).
- 395 13. Iozzo, R. V. & Schaefer, L. Proteoglycan form and function: A comprehensive
- nomenclature of proteoglycans. *Matrix Biol* **42**, 11–55 (2015).
- 397 14. Gesslbauer, B., Rek, A., Falsone, F., Rajkovic, E. & Kungl, A. J. Proteoglycanomics:
- tools to unravel the biological function of glycosaminoglycans. *Proteomics* **7**, 2870–2880
- 399 (2007).
- 400 15. Weyers, A. et al. A Structural Analysis of Glycosaminoglycans from Lethal and
- 401 Nonlethal Breast Cancer Tissues: Toward a Novel Class of Theragnostics for
- 402 Personalized Medicine in Oncology? *OMICS* **16**, 79–89 (2012).
- 403 16. Gatto, F. et al. Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive
- 404 Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study. *JCO*
- 405 *Precision Oncology* **7**, e2200361 (2023).
- 406 17. Gatto, F. et al. Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in
- 407 Nonmetastatic Renal Cell Carcinoma-A Prospective Cohort Study. Eur Urol Open Sci 42,
- 408 30–39 (2022).
- 409 18. Al-Nakouzi, N. et al. Reformation of the chondroitin sulfate glycocalyx enables
- progression of AR-independent prostate cancer. *Nat Commun* **13**, 4760 (2022).
- 411 19. Theocharis, A. D., Vynios, D. H., Papageorgakopoulou, N., Skandalis, S. S. &
- Theocharis, D. A. Altered content composition and structure of glycosaminoglycans and

- 413 proteoglycans in gastric carcinoma. The International Journal of Biochemistry & Cell
- 414 *Biology* **35**, 376–390 (2003).
- 415 20. Balbisi, M. et al. Inter- and intratumoral proteomics and glycosaminoglycan
- characterization of ALK rearranged lung adenocarcinoma tissues: a pilot study. Sci Rep
- **13**, 6268 (2023).
- 418 21. Li, G. *et al.* Glycosaminoglycans and glycolipids as potential biomarkers in lung cancer.
- 419 *Glycoconj J* **34**, 661–669 (2017).
- 420 22. Cohen, J. F. et al. STARD 2015 guidelines for reporting diagnostic accuracy studies:
- 421 explanation and elaboration. *BMJ Open* **6**, e012799 (2016).
- 422 23. Detterbeck, F. C., Boffa, D. J., Kim, A. W. & Tanoue, L. T. The Eighth Edition Lung
- 423 Cancer Stage Classification. *Chest* **151**, 193–203 (2017).
- 424 24. William D. Travis, Elisabeth Brambilla, H. Konrad Müller-Hermelink, & Curtis C. Harris.
- 425 Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. (IARC
- 426 Press, Lyon, 2004).
- 427 25. Tamburro, D. et al. Analytical performance of a standardized kit for mass spectrometry-
- based measurements of human glycosaminoglycans. *Journal of Chromatography B* **1177**,
- 429 122761 (2021).
- 430 26. Volpi, N., Galeotti, F., Yang, B. & Linhardt, R. J. Analysis of glycosaminoglycan-
- derived, precolumn, 2-aminoacridone—labeled disaccharides with LC-fluorescence and
- 432 LC-MS detection. *Nat Protoc* **9**, 541–558 (2014).
- 433 27. Qvick, A. *et al.* Liquid biopsy as an option for predictive testing and prognosis in patients
- with lung cancer. *Mol Med* **27**, 68 (2021).
- 28. Kruschke, J. K. Bayesian estimation supersedes the t test. J Exp Psychol Gen 142, 573–
- 436 603 (2013).

- 437 29. Vehtari, A., Gelman, A., Simpson, D., Carpenter, B. & Bürkner, P.-C. Rank-
- Normalization, Folding, and Localization: An Improved R<sup>^</sup> for Assessing Convergence of
- 439 MCMC (with Discussion). *Bayesian Analysis* **16**, 667–718 (2021).
- 30. Bürkner, P.-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *Journal*
- 441 *of Statistical Software* **80**, 1–28 (2017).
- 31. Makowski, D., Ben-Shachar, M. S. & Lüdecke, D. bayestestR: Describing Effects and
- their Uncertainty, Existence and Significance within the Bayesian Framework. *Journal of*
- 444 *Open Source Software* **4**, 1541 (2019).
- 32. Pál, D. et al. Compositional Analysis of Glycosaminoglycans in Different Lung Cancer
- 446 Types-A Pilot Study. *Int J Mol Sci* **24**, 7050 (2023).
- 33. Mattox, A. K. *et al.* The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals
- and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer. Cancer Discov 13,
- 449 2166–2179 (2023).
- 450 34. Bratulic, S. et al. Noninvasive detection of any-stage cancer using free
- 451 glycosaminoglycans. *Proceedings of the National Academy of Sciences* **119**,
- 452 e2115328119 (2022).
- 453 35. Wang, F. et al. Ultra-short cell-free DNA fragments enhance cancer early detection in a
- 454 multi-analyte blood test combining mutation, protein and fragmentomics. Clin Chem Lab
- 455 *Med* **62**, 168–177 (2024).
- 456 36. D'Ambrosi, S. et al. Combinatorial Blood Platelets-Derived circRNA and mRNA
- 457 Signature for Early-Stage Lung Cancer Detection. *Int J Mol Sci* **24**, 4881 (2023).
- 458 37. Bratulic, S. et al. Analysis of normal levels of free glycosaminoglycans in urine and
- plasma in adults. *Journal of Biological Chemistry* **298**, (2022).
- 38. da Silva, M. N. R., Mendes, A., Martins, J. R. M., Tobias-Machado, M. & Pinhal, M. A.
- da S. Prospective Evaluation of Chondroitin Sulfate, Heparan Sulfate and Hyaluronic
- 462 Acid in Prostate Cancer. *Int Braz J Urol* **44**, 1139–1146 (2018).

- 39. Saito, A. & Munakata, H. Analysis of plasma proteins that bind to glycosaminoglycans.
- 464 *Biochim Biophys Acta* **1770**, 241–246 (2007).

- 465 40. Prabhakar, V. & Sasisekharan, R. The biosynthesis and catabolism of
- galactosaminoglycans. Adv Pharmacol **53**, 69–115 (2006).